Source: Υπουργείο Υγείας (CY) Revision Year: 2018 Publisher: Delorbis Pharmaceuticals Ltd., 17 Athinon Street, Ergates Industrial Area, 2643 Ergates, P.O. Box 28629, 2081 Lefkosia, Cyprus, European Union
Naprorex 250 mg Tablets.
Naprorex 500 mg Tablets.
| Pharmaceutical Form |
|---|
|
Tablets. For Naprorex 250 mg tablets: White, concave, round tablets, 10 mm diameter in size, scored on one side. For Naprorex 500 mg tablets: White, concave, round tablets, 12 mm diameter in size, scored on one side. |
For Naprorex 250 mg tablets: Each tablet contains 250 mg of naproxen.
For Naprorex 500 mg tablets: Each tablet contains 500 mg of naproxen.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Naproxen |
Naproxen is a non-steroidal anti-inflammatory analgesic compound with antipyretic properties as has been demonstrated in classical animal test systems. Naproxen exhibits its anti-inflammatory effect even in adrenalectomised animals, indicating that its action is not mediated through the pituitary-adrenal axis. |
| List of Excipients |
|---|
|
Magnesium stearate |
Naprorex 250 and 500 mg tablets are packed in Aluminum/PVC blisters of 1x10 and 2x10 tablets.
Not all pack sizes may be marketed.
Delorbis Pharmaceuticals Ltd., 17 Athinon Street, Ergates Industrial Area, 2643 Ergates, P.O. Box 28629, 2081 Lefkosia, Cyprus, European Union
Naprorex 250 tablets: 14662
Naprorex 500 tablets: 14664
Date of first authorisation: 4 April 1994
| Drug | Countries | |
|---|---|---|
| NAPROREX | Cyprus |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
